{"id":"mesuximide","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute intermittent porphyria","Aggressive behavior","Depressive disorder","Disease of liver","Kidney disease","Neutropenic disorder","Suicidal thoughts","Systemic lupus erythematosus"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Voltage-gated T-type calcium channel"},"_scrapedAt":"2026-03-28T02:00:35.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Mesuximide","title":"Mesuximide","extract":"Mesuximide is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin. The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent."},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Absence seizure","diseaseId":"absence-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy","diseaseId":"epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03196466","phase":"","title":"Population Pharmacokinetics of Antiepileptic in Pediatrics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-19","conditions":"Epilepsy","enrollment":753}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"THROMBOCYTOPENIA"},{"count":5,"reaction":"FALL"},{"count":5,"reaction":"HOSPITALISATION"},{"count":4,"reaction":"ATAXIA"},{"count":4,"reaction":"HAEMODIALYSIS"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"SOMNOLENCE"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":2,"reaction":"BRADYPHRENIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"mesuximide","genericName":"mesuximide","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mesuximide is a succinimide anticonvulsant medication sold under the tradenames Petinutin and Celontin. It is used to treat epilepsy, with its therapeutic efficacy attributed to its pharmacologically active metabolite, N-desmethylmethosuximide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}